Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOrtiz-Sanjuán, Francisco-
dc.contributor.authorBlanco, Ricardo-
dc.contributor.authorRiancho-Zarrabeitia, Leyre-
dc.contributor.authorCastañeda, Santos-
dc.contributor.authorOlivé, Alejandro-
dc.contributor.authorRiveros, Anne-
dc.contributor.authorVelloso-Feijoo, María L-
dc.contributor.authorNarváez, Javier-
dc.contributor.authorJiménez-Moleón, Inmaculada-
dc.contributor.authorMaiz-Alonso, Olga-
dc.contributor.authorOrdóñez, Carmen-
dc.contributor.authorBernal, José A-
dc.contributor.authorHernández, María V-
dc.contributor.authorSifuentes-Giraldo, Walter A-
dc.contributor.authorGómez-Arango, Catalina-
dc.contributor.authorGalíndez-Agirregoikoa, Eva-
dc.contributor.authorBlanco-Madrigal, Juan-
dc.contributor.authorOrtiz-Santamaria, Vera-
dc.contributor.authordel Blanco-Barnusell, Jordi-
dc.contributor.authorDe Dios, Juan R-
dc.contributor.authorMoreno, Mireia-
dc.contributor.authorFiter, Jordi-
dc.contributor.authorde los Riscos, Marina-
dc.contributor.authorCarreira, Patricia-
dc.contributor.authorRodriguez-Valls, María J-
dc.contributor.authorGonzález-Vela, M Carmen-
dc.contributor.authorCalvo-Río, Vanesa-
dc.contributor.authorLoricera, Javier-
dc.contributor.authorPalmou-Fontana, Natalia-
dc.contributor.authorPina, Trinitario-
dc.contributor.authorLlorca, Javier-
dc.contributor.authorGonzález-Gay, Miguel A-
dc.identifier.citationOrtiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review. Medicine (Baltimore). 2015 ; 94(39):e1554es_ES
dc.identifier.issn1536-5964 (Online)es_ES
dc.identifier.issn0025-7974 (Print)es_ES
dc.description.abstractAdult-onset Still's disease (AOSD) is often refractory to standard therapy. Anakinra (ANK), an interleukin-1 receptor antagonist, has demonstrated efficacy in single cases and small series of AOSD. We assessed the efficacy of ANK in a series of AOSD patients. Multicenter retrospective open-label study. ANK was used due to lack of efficacy to standard synthetic immunosuppressive drugs and in some cases also to at least 1 biologic agent. Forty-one patients (26 women/15 men) were recruited. They had a mean age of 34.4 ± 14 years and a median [interquartile range (IQR)] AOSD duration of 3.5 [2-6] years before ANK onset. At that time the most common clinical features were joint manifestations 87.8%, fever 78%, and cutaneous rash 58.5%. ANK yielded rapid and maintained clinical and laboratory improvement. After 1 year of therapy, the frequency of joint and cutaneous manifestations had decreased to 41.5% and to 7.3% respectively, fever from 78% to 14.6%, anemia from 56.1% to 9.8%, and lymphadenopathy from 26.8% to 4.9%. A dramatic improvement of laboratory parameters was also achieved. The median [IQR] prednisone dose was also reduced from 20 [11.3-47.5] mg/day at ANK onset to 5 [0-10] at 12 months. After a median [IQR] follow-up of 16 [5-50] months, the most important side effects were cutaneous manifestations (n = 8), mild leukopenia (n = 3), myopathy (n = 1), and infections (n = 5). ANK is associated with rapid and maintained clinical and laboratory improvement, even in nonresponders to other biologic agents. However, joint manifestations are more refractory than the systemic manifestations.es_ES
dc.description.sponsorshipThis work was partially supported by RETICS Programs, RD08/0075m (RIER), and RD12/0009/0013 from ‘‘Instituto de Salud Carlos III’’ (ISCIII) (Spain)es_ES
dc.publisherLippincott, Williams & Wilkinses_ES
dc.subjectQuimioterapia combinadaes_ES
dc.subjectProteína antagonista del receptor de interleucina 1es_ES
dc.subjectMediana edades_ES
dc.subjectEstudios retrospectivoses_ES
dc.subjectEnfermedad de Still del adultoes_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Age Groups::Adultes_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combinationes_ES
dc.subject.meshMedical Subject Headings::Check Tags::Femalees_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agentses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukin 1 Receptor Antagonist Proteines_ES
dc.subject.meshMedical Subject Headings::Check Tags::Malees_ES
dc.subject.meshMedical Subject Headings::Persons::Persons::Age Groups::Adult::Middle Agedes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisonees_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studieses_ES
dc.subject.meshMedical Subject Headings::Diseases::Immune System Diseases::Autoimmune Diseases::Arthritis, Rheumatoid::Still's Disease, Adult-Onsetes_ES
dc.titleEfficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.es_ES
dc.rights.accessRightsAcceso abiertoes_ES
dc.contributor.authoraffiliation[Ortiz-Sanjuán,F; Blanco,R; Riancho-Zarrabeitia,L; González-Vela,MC; Calvo-Río,V; Loricera,J; Palmou-Fontana,N; Pina,T; González-Gay,MA] Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander. [Castañeda,S] Hospital Universitario de La Princesa, IIS Princesa Madrid, Madrid. [Olivé,A; Riveros,A] Hospital Universitario Germans Trias i Pujol, Badalona. [Velloso-Feijoo,ML] Hospital Valme, Sevilla. [Narváez,J] Hospital Universitario de Bellvitge Hospitalet, Barcelona. [Jiménez-Moleón,I] Hospital San Cecilio, Granada. [Maiz-Alonso,O] HU Donostia, San Sebastián. [Ordóñez,C] HRU Carlos Haya, Málaga. [Bernal,JA] HGU, Alicante, Alicante. [Hernández,MV] Hospital Clinic of Barcelona, Barcelona. [Sifuentes-Giraldo,WA] Hospital Ramón y Cajal, Madrid. [Gómez-Arango,C; Galíndez-Agirregoikoa,E; Blanco-Madrigal,J] Hospital Universitario Basurto, Bilbao. [Ortiz-Santamaria,V] Hospital General Granollers, Granollers, Spain. [del Blanco-Barnusell,J] H Sant Jaume, Calella. [De Dios,JD] HU Álava, Vitoria. [Moreno,M] HU Parc Taulí, Sabadell. [Fiter,J] HU Son Espases, Palma de Mallorca, Mallorca. [de los Riscos,M; Carreira,P] Hospital Universitario 12 de Octubre, Madrid. [Rodriguez-Valls,MJ] Hospital de Jerez, Jerez. [Llorca,JL] Universidad de Cantabria, IDIVAL, Santander. CIBER Epidemiology and Public Health (CIBERESP), Santander Spain.es_ES
dc.type.subtypeArtículo originales_ES
Appears in Collections:01- Artículos - AGS Sur de Sevilla
01- Artículos - Complejo Hospitalario Universitario de Granada
01- Artículos - Hospital de Jerez
01- Artículos - Hospital Regional de Málaga

Files in This Item:
File Description SizeFormat 
OrtizSanjuan_EfficacyOfAnakinra.pdfArtículo publicado278,61 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons